SI-BONE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 06, 2023 at 04:10 pm EST
Share
SI-BONE, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 34.01 million compared to USD 26.43 million a year ago. Net loss was USD 10.02 million compared to USD 14.16 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.41 a year ago. Diluted loss per share from continuing operations was USD 0.25 compared to USD 0.41 a year ago.
For the nine months, sales was USD 100.03 million compared to USD 74.46 million a year ago. Net loss was USD 32.35 million compared to USD 50.08 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 1.47 a year ago.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE, INC. 
